Recruiting

An Efficacy Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Participants With Newly Diagnosed Ph+ ALL

The purpose of this study is to compare the efficacy of the drugs ponatinib versus imatinib, administered as first-line therapy in combination with reduced-intensity chemotherapy, in participants with newly diagnosed Ph+ ALL, as measured by the minimal residual disease (MRD)-negative complete remission (CR) at the end of induction.

Status
Recruiting

Closed for Recruitment

Treatment-free Remission Accomplished With Dasatinib in Patients With CML (TRAD)

The purpose of this study is to find out how to increase the potential for achieving an "operational cure" from chronic myeloid leukemia. An "operational cure" is a state in which a person does not require further treatment, although there may be some remaining cancer cells. Patients would normally remain on a TK inhibitor indefinitely within a standard of care setting for chronic myeloid leukemia. Within this clinical trial, patients will discontinue their TK inhibitor prematurely. If any signs of progression are identified, dasatinib will be introduced.

Status
Closed for Recruitment
Principal Investigator
Donna Forrest
Body Locations and Systems
Leukemia
Area
Vancouver
Age
18 and above
Subscribe to Leukemia